Adolescent exposure to chronic delta-9-tetrahydrocannabinol blocks opiate dependence in maternally deprived rats

Neuropsychopharmacology

Volumn 34, Issue 11, 2009, Pages 2469-2476

  Morel, Lydie J ^a,b,c,e   Giros, Bruno ^a,b,c,d   Daugé, Valérie ^a,b,c,f  

^a INSERM   (France)

^b CNRS   (France)

^c SORBONNE UNIVERSITÉ   (France)

^d DOUGLAS MENTAL HEALTH UNIVERSITY INSTITUTE   (Canada)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f Groupe Enzymologie Moléculaire et Fonctionnelle   (France)

Author keywords

Adolescent chronic delta 9 tetrahydrocannabinol; CB1 m opioid receptors; Maternal deprivation; Morphine place preference; Oral morphine self administration; Preproenkephalin mRNA

Indexed keywords

CANNABINOID 1 RECEPTOR; DRONABINOL; MESSENGER RNA; MORPHINE; MU OPIATE RECEPTOR; PREPROENKEPHALIN;

ADOLESCENCE; ADOLESCENT; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CAUDATE NUCLEUS; CONTROLLED STUDY; CORPUS STRIATUM; DRUG DOSE INCREASE; DRUG SELF ADMINISTRATION; EXPOSURE; FEMALE; HOMEOSTASIS; LONG TERM EXPOSURE; MATERNAL DEPRIVATION; MESENCEPHALON; NONHUMAN; NUCLEUS ACCUMBENS; OPIATE ADDICTION; PLACE PREFERENCE; PRIORITY JOURNAL; PUTAMEN; RAT; RECEPTOR DENSITY; RELATIVE DENSITY;

AGING; ANALGESICS, NON-NARCOTIC; ANALGESICS, OPIOID; ANIMALS; BRAIN; CONDITIONING, CLASSICAL; ENKEPHALINS; MALE; MATERNAL DEPRIVATION; MORPHINE; OPIOID-RELATED DISORDERS; PROTEIN PRECURSORS; RATS; RATS, LONG-EVANS; RECEPTOR, CANNABINOID, CB1; RECEPTORS, OPIOID, MU; RNA, MESSENGER; SELF ADMINISTRATION; SPACE PERCEPTION; TETRAHYDROCANNABINOL; TIME FACTORS;

EID: 70349154961     PISSN: 0893133X     EISSN: None     Source Type: Journal    
DOI: 10.1038/npp.2009.70     Document Type: Article

References (47)

1. Andersen SL (2003). Trajectories of brain development: point of vulnerability or window of opportunity? Neurosci Biobehav Rev 27 : 3-18.
2. Bardo MT, Bevins RA (2000). Conditioned place preference: what does it add to our preclinical understanding of drug reward? Psychopharmacology 153: 31-43.
3. Belue RC, Howlett AC, Westlake TM, Hutchings DE (1995). The ontogeny of cannabinoid receptors in the brain of postnatal and aging rats. Neurotoxicol Teratol 17: 25-30.
4. Biscaia M, Fernàndez B, Higuera-Matas A, Miguèns M, Viveros M-P, García-Lecumberri C et al (2008). Sex-dependent effects of periadolescent exposure to the cannabinoid agonist CP-55 940 on morphine self-administration behaviour and the endogenous opioid system. Neuropharmacology 54: 863-873.
5. Cadoni C, Pisanu A, Solinas M, Acquas E, Di Chiara G (2001). Behavioural sensitization after repeated exposure to delta-9-tetrahydrocannabinol and cross-sensitization with morphine. Psychopharmacology 158: 259-266.
6. Corchero J, Garcia-Gil L, Manzanares J, Fernandez-Ruiz JJ, Fuentes JA, Ramos JA (1998). Perinatal delta-9 tetrahydrocannabinol exposure reduces proenkephalin gene expression in the caudate-putamen of adult female rats. Life Sci 63: 843-850.
7. Ellgren M, Spano SM, Hurd YL (2007). Adolescent cannabis exposure alters opiate intake and opioid limbic neuronal populations in adult rats. Neuropsychopharmacology 32: 607-615.
8. Gardner EL, Vorel SR (1998). Cannabinoid transmission and reward-related events. Neurobiol Disease 5: 502-533.
9. Herkenham M, Lynn AB, Johnson MR, Melvin LS, De Costa BR, Rice KC (1991). Characterization and localization of cannabinoid receptors in rat brain: a quantitative in vitro autoradiographic study. J Neurosci 11: 563-583.
10. Howlett AC (1995). Pharmacology of cannabinoid receptors. Annu Rev Pharmacol Toxicol 35: 607-634.
11. Hohmann AF, Herkenham H (2000). Localization of cannabinoid CB(1) receptor mRNA in neuronal subpopulations of rat striatum: a double-label in situ hybridization study. Synapse 37 : 71-80.
12. Hoffman AF, Oz M, Caulder T, Lupica CR (2003). Functional tolerance and blockade of long-term depression at synapses in the nucleus accumbens after chronic cannabinoid exposure. J Neurosci 23: 4815-4820.
13. Jardinaud F, Roques BP, Noble F (2006). Tolerance to the reinforcing effects of morphine in delta9-tetrahydrocannabinol treated mice. Behav Brain Res 173: 255-261.
14. Kieffer BL (1999). Opioids: first lessons from knockout mice. Trends Pharmacol Sci 20: 19-26.
15. Lamarque S, Taghzouti K, Simon H (2001). Chronic treatment with delta(9)-tetrahydrocannabinol enhances the locomotor response to amphetamine and heroine. Implications for vulnerability to drug addiction. Neuropharmacology 41: 118-129.
16. Ledent C, Valverde O, Cossu G, Petitet F, Aubert JF, Beslot F et al (1999). Unresponsiveness to cannabinoids and reduced addictive effects of opiates in CB1, receptor knockout mice. Science 228: 401-404.
17. McKinney DL, Cassidy MP, Collier LM, Martin BR, Wiley JL, Selley DE et al (2008). Dose-related differences in the regional pattern of cannabinoid receptor adaptation and in vivo tolerance development to delta9- tetrahydrocannabinol. J Pharmacol Exp Ther 324: 664-673.
18. Mansour A, Fox CA, Akil H, Watson SJ (1995). Opioid-receptor mRNA expression in the rat CNS: anatomical and functional implications. Trends Neurosci 18: 22-29.
19. Manzanedo C, Aguilar MA, Rodriguez-Arias M, Navarro M, Minarro J (2004). Cannabinoid agonist-induced sensitization to morphine place preference in mice. NeuroReport 15: 1373-1376.
20. Mason Jr DJ, Lowe J, Welch SP (1999). A diminution of delta-9-tetrahydrocannabinol modulation of dynorphin A(1-17) in conjunction with tolerance development. Eur J Pharmacol 381: 105-111.
21. Matsuda L, Lolait SJ, Brownstein MJ, Young AC, Bonner TI (1990). Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 346: 561-564.
22. Navarro M, Carrera MRA, Fratta W, Valverde O, Cossu G, Fattore L et al (2001). Functional interaction between opioid and cannabinoid receptors in drug self-administration. J Neurosci 15: 5344-5350.
23. Norwood CS, Cornish JL, Mallet PE, McGregor IS (2003). Preexposure to the cannabinoid receptor agonist CP 55940 enhances morphine behavioral sensitization and alters morphine self-administration in Lewis rats. Eur J Pharmacol 28: 105-114.
24. Paxinos G, Watson C (1997). The Rat Brain in Stereotaxic Coordinates. Academic Press: New York.
25. Pertwee RG (2008). The diverse CB1 and CB2 receptor pharmacology of the three plant cannabinoids: D9-tetrahydrocannabinol, cannabidiol and D9-tetrahydrocannabivarin. Br J Pharmacol 153: 199-215.
26. Pickel VM, Chan J, Kash TL, Rodriguez JJ, Mackie K (2004). Compartment-specific localization of cannabinoid 1 (CB1) and m opioid receptors in rat nucleus accumbens. Neuroscience 127: 101-112.
27. Pistis M, Perra S, Pillolla G, Melis M, Muntoni A-L, Gessa GL (2004). Adolescent exposure to cannabinoids induces long-lasting changes in the response to drugs of abuse of rat midbrain dopamine neurons. Biol Psychiatry 56: 86-94.
28. Rios C, Gomes I, Devi LA (2006). m opioid and CB1 cannabinoid receptors interactions: reciprocal inhibition of receptor signaling and neuritogenesis. Br J Pharmacol 148: 387-395.
29. Rodriguez JJ, Mackie K, Pickel VM (2001). Ultrastructural localization of the CB1 cannabinoid receptor in mu-opioid receptor patches of the rat caudate putamen nucleus. J Neurosci 24 : 1673-1679.
30. Rodriguez de Fonseca F, Ramos JA, Bonnin A, Fernandez-Ruiz JJ (1993). Presence of cannabinoid binding sites in the brain from early postnatal ages. Neuroreport 4: 135-138.
31. Roloff AM, Thayer SA (2009). Modulation of excitatory synaptic transmission by D9-tetrahydrocannabinol switches from agonist to antagonist depending on firing rate. Mol Pharmacol 75 : 892-900.
32. Romero J, Berrendero F, Manzanares J, Pérez A, Corchero J, Fuentes JA et al (1998). Time-course of the cannabinoid receptor down-regulation in the adult rat brain caused by repeated exposure to delta-9-tetrahydrocannabinol. Synapse 30: 298-308.
33. Rubino T, Vigano D, Massi P, Spinello M, Zagato E, Giagnoni G (2000). Chronic delta-9-tetrahydrocannabinol treatment increases cAMP levels and cAMP-dependent protein kinase activity in some rat brain regions. Neuropharmacology 39: 1331-1336.
34. Schoffelmeer ANM, Hogenboom F, Wardeh G, De Vries TJ (2006). Interactions between CB1 cannabinoid and m opioid receptors mediating inhibition of neurotransmitter release in rat nucleus accumbens core. Neuropharmacology 51: 773-781.
35. Shippenberg TS, Bals-Kubik R, Herz A (1993). of the neurochemical substrates mediating the motivational effects of opioids: role of the mesolimbic dopamine system and D-1 vs D-2 dopamine receptors. J Pharmacol Exp Ther 265: 53-59.
36. Sim-Selley LJ (2003). Regulation of cannabinoid CB1 receptors in the central nervous system by chronic cannabinoids. Crit Rev Neurobiol 15: 91-119.
37. Singh ME, McGregor IS, Mallet PE (2005). Repeated exposure to delta9-tetrahydrocannabinol alters heroin-induced locomotor sensitisation and Fosimmunoreactivity. Neuropharmacology 49 : 1189-1200.
38. Singh ME, McGregor IS, Mallet PE (2006). Perinatal exposure to delta-9 tetrahydrocannabinol alters heroin-induced place conditioning and Fosimmunoreactivity. Neuropsychopharmacology 31 : 58-69.
39. Steiner H, Bonner TI, Zimmer AM, Kitai ST, Zimmer A (1999). Altered gene expression in striatal projection neurons in CB1 cannabinoid receptor knockout mice. Proc Natl Acad Sci USA 96: 5786-5790.
40. Tanda G, Goldberg SR (2003). Cannabinoids: reward, dependence, and underlying neurochemical mechanisms- a review of recent preclinical data. Psychopharmacology 169: 115-134.
41. Valverde O, Noble F, Beslot F, Daugé V, Fournié-Zaluski M-C, Roques BP (2001). D9Ftetrahydrocannabinol releases and facilitates the effects of endogenous enkephalins: reduction in morphine withdrawal syndrome without change in rewarding effect. Eur J Neurosci 13: 1816-1824.
42. Van Ree JM, Niesink RJ, Van Wolfswinkel L, Ramsey NF, Kornet MM, Van Furth WR et al (2000). Endogenous opioids and reward. Eur J Pharmacol 405: 89-101.
43. Vazquez V, Weiss S, Giros B, Martres M-P, Daugé V (2007). Maternal deprivation and handling modify the effect of the dopamine D3 receptor agonist, BP 897 on morphine-conditioned place preference in rats. Psychopharmacology 193: 475-486.
44. Vazquez V, Penit-Soria J, Durand C, Besson MJ, Giros B, Daugé V (2005). Maternal deprivation increases vulnerability to morphine dependence and disturbs the enkephalinergic system in adulthood. J Neurosci 25: 4453-4462.
45. Vazquez V, Giros B, Daugé V (2006). Maternal deprivation specifically enhances vulnerability for opiate dependence. Behav Pharmacol 17: 715-724.
46. Yao L, McFarland K, Fan P, Jiang Z, Ueda T, Diamond I (2006). Adenosine A2a blockade prevents synergy between mopiate and cannabinoid CB1 receptors and eliminates heroin-seeking behavior in addicted rats. Proc Natl Acad Sci USA 103: 7877-7882.
47. Wolffgramm J, Heyne A (1995). From controlled drug intake to loss of control: the irreversible development of drug addiction in the rat. Behav Brain Res 70: 77-94.